Novo Nordisk AS
NOV0
Company Profile
Business description
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Contact
Novo Alle 1
Bagsvaerd2880
DNKT: +45 44448888
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
77,406
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,768.60 | 1.60 | -0.02% |
| CAC 40 | 7,833.44 | 28.77 | 0.37% |
| DAX 40 | 24,354.29 | 77.81 | 0.32% |
| Dow JONES (US) | 42,427.74 | 91.90 | -0.22% |
| FTSE 100 | 8,829.20 | 27.91 | 0.32% |
| HKSE | 23,906.97 | 252.94 | 1.07% |
| NASDAQ | 19,460.49 | 61.53 | 0.32% |
| Nikkei 225 | 37,554.49 | 192.96 | -0.51% |
| NZX 50 Index | 12,577.15 | 82.44 | 0.66% |
| S&P 500 | 5,970.81 | 0.44 | 0.01% |
| S&P/ASX 200 | 8,538.90 | 2.90 | -0.03% |
| SSE Composite Index | 3,384.10 | 7.90 | 0.23% |